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N
europathic pain exerts a substantial
impact on quality of life, particu-
larly by causing considerable inter-
ference in sleep, daily activities, and
enjoyment of life. Chronic neuropathic
pain is present in 13–26% of diabetic pa-
tients (1–4). In a recent survey from
Augsburg, Germany, the prevalence of
painful polyneuropathy was found to be
13.3% in diabetic subjects, 8.7% in indi-
viduals with impaired glucose tolerance,
4.2% in individuals with impaired fasting
glucose, and 1.2% in individuals with
normal glucose tolerance (3). Indepen-
dent factors signiﬁcantly associated with
diabetic painful neuropathy (DPN) were
age, weight, and peripheral arterial dis-
ease. Pain is a subjective symptom of ma-
jor clinical importance, since it is often
this complaint that motivates patients to
seek health care. However, in a survey
from the U.K., only 65% of diabetic pa-
tients received treatment for their neuro-
pathic pain, although 96% had reported
thepaintotheirphysician.Paintreatment
consisted of antidepressants in 43.5% of
cases, anticonvulsants in 17.4%, opiates
in39%,andalternativetreatmentsin30%
(combinationspossible).Whereas77%of
the patients reported persistent pain over
5 years, 23% were pain free over at least 1
year (1). Thus, neuropathic pain persists
in the majority of diabetic patients over
periods of several years.
MANIFESTATIONS
OF PAINFUL
NEUROPATHY — Chronic DPN with
persistent or episodic pain that typically
may worsen at night, and improve during
walking,islocalizedpredominantlyinthe
feet.Thepainisoftendescribedasadeep-
seated ache, but there may be superim-
posedlancination,oritmaybeofburning
thermal quality. In a clinical survey in-
cluding 105 patients with DPN, the fol-
lowing locations of pain were most
frequent:96%feet,69%ballsoffeet,67%
toes, 54% dorsum of foot, 39% hands,
37% plantum of foot, 37% calves, and
32% heels. The pain was most often de-
scribed by the patients as “burning/hot,”
“electric,” “sharp,” “achy,” and “tingling,”
which was worse at night and when tired
or stressed (5). The average pain intensity
wasmoderate,5.75/10ona0–10scale,
with the “least” and “most” pain being 3.6
and 6.9/10, respectively. Evoked pain,
such as allodynia (pain due to a stimulus
that does not normally cause pain, e.g.,
stroking) and hyperalgesia (severe pain
due to a stimulus that normally causes
slight pain, e.g., a pin-prick) may be
present. The symptoms may be accompa-
nied by sensory loss, but patients with se-
verepainmayhavefewclinicalsigns.Pain
may persist over several years (6) causing
considerable disability and impaired
quality of life in some patients (5),
whereas it remits partially or completely
in others (7,8), despite further deteriora-
tion in small ﬁber function (8). Pain re-
mission tends to be associated with
sudden metabolic change, short duration
ofpainordiabetes,precedingweightloss,
and less severe sensory loss (7,8).
AcuteDPNhasbeendescribedasasep-
arateclinicalentity(9).Itisencounteredin-
frequentlyinbothtype1andtype2diabetic
patients presenting with continuous burn-
ing pain, particularly in the soles (“like
walking on burning sand”) with nocturnal
exacerbation. A characteristic feature is a
cutaneous contact discomfort to clothes
and sheets that can be objectiﬁed as hyper-
sensitivity to tactile (allodynia) and painful
stimuli (hyperalgesia). Motor function is
preserved and sensory loss may be only
slight, being greater for thermal than for vi-
bratory sensation. The onset is associated
with, and preceded by precipitous and se-
vere weight loss. Depression and erectile
dysfunction are constant features. Weight
losshasbeenshowntorespondtoadequate
glycemic control, and the severe manifesta-
tions subsided within 10 months in all
cases. No recurrences were observed after
follow-up periods of up to 6 years (9). The
syndrome of acute DPN seems to be equiv-
alent to “diabetic cachexia” as described by
Ellenberg(10).Ithasalsobeendescribedin
girls with anorexia nervosa and diabetes in
association with weight loss (11).
The term “insulin neuritis” was used
by Caravati (12) to describe a case with
precipitation of acute DPN several weeks
after the institution of insulin treatment.
Sural nerve biopsy showed signs of
chronic neuropathy with prominent re-
generative activity (13), as well as
epineurial arteriovenous shunting, and a
ﬁne network of vessels, resembling the
new vessels of the retina, which may lead
to a steal effect rendering the endo-
neuriumischemic(14).Thismayoccurin
analogy to the transient deterioration of a
preexisting retinopathy after rapid im-
provement in glycemic control.
The following ﬁndings should alert
the physician to consider causes for neu-
ropathy other than diabetes and referral
for a detailed neurological workup:
● Pronounced asymmetry of the neuro-
logical deﬁcits
● Predominant motor deﬁcits, mononeu-
ropathy,andcranialnerveinvolvement
● Rapid development or progression of
the neuropathic impairments
● Progression of the neuropathy despite
optimal glycemic control
● Development of symptoms and deﬁcits
only in the upper limbs
● Family history of nondiabetic neuropathy
● Diagnosis of neuropathy cannot be as-
certained by clinical examination
The most important differential diag-
noses from the general medicine perspec-
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alcohol abuse, uremia, hypothyroidism,
vitamin B12 deﬁciency, peripheral arte-
rial disease, cancer, inﬂammatory and in-
fectious diseases, and neurotoxic drugs.
PHARMACOLOGICAL
TREATMENT BASED ON
PATHOGENETIC
CONCEPTS— Recent experimental
studies suggest a multifactorial pathogen-
esis of diabetic neuropathy. From the
clinicalpointofview,itisnoteworthythat
based on the various pathogenetic mech-
anisms, therapeutic approaches could be
derived, some of which have been evalu-
ated in randomized clinical trials. These
drugs have been designed to favorably in-
ﬂuence the underlying neuropathic pro-
cess, rather than for symptomatic pain
treatment. Because in the foreseeable fu-
ture normoglycemia will not be achiev-
able in the majority of diabetic patients,
the advantage of the aforementioned
treatmentapproachesisthattheymayex-
ert their effects despite prevailing hyper-
glycemia. For clinical use, -lipoic acid is
licensed and used for treatment of symp-
tomatic polyneuropathy in several coun-
tries worldwide, whereas epalrestat is
marketed in Japan and India.
-Lipoic acid (thioctic acid)
Accumulating evidence suggests that free
radical–mediated oxidative stress is im-
plicated in the pathogenesis of diabetic
neuropathy by inducing neurovascular
defects that result in endoneurial hypoxia
and subsequent nerve dysfunction. Anti-
oxidant treatment with -lipoic acid has
been shown to prevent these abnormalities
in experimental diabetes, thus providing a
rationale for potential therapeutic value in
diabetic patients. In Germany, -lipoic
acid is licensed and has been used for
treatment of symptomatic diabetic neu-
ropathy for over 40 years. According to a
meta-analysis comprising 1,258 patients,
infusions of -lipoic acid (600 mg i.v./
day) ameliorated neuropathic symptoms
and deﬁcits after 3 weeks (15). Moreover,
the Symptomatic Diabetic Neuropathy
(SYDNEY) 2 trial suggests that treatment
for 5 weeks using 600 mg q.d. -lipoic
acid orally reduces the chief symptoms of
diabetic polyneuropathy including pain,
paresthesias,andnumbnesstoaclinically
meaningful degree (16). In a multicenter
randomized double-masked parallel
group clinical trial (NATHAN 1), 460 di-
abetic patients with stage 1 or stage 2a
polyneuropathy were randomly assigned
to oral treatment with -lipoic acid 600
mg q.d. (n  233) or placebo (n  227)
for4years.After4years,neuropathicdef-
icits progressed signiﬁcantly on placebo
and improved on -lipoic acid, and the
drug was well tolerated throughout the
trial(17).Clinicalandpostmarketingsur-
veillance studies have revealed a highly
favorable safety proﬁle of this drug.
SYMPTOMATIC
PHARMACOLOGICAL
TREATMENT OF PAINFUL
NEUROPATHY— Diabetic painful
neuropathymayconstituteaconsiderable
management problem. The efﬁcacy of a
single therapeutic agent is not the rule,
and simple analgesics are usually inade-
quate to control the pain. Therefore, var-
ious therapeutic schemes have been
previously proposed, but none have been
validated. Nonetheless, there is agree-
ment that patients should be offered the
available therapies in a stepwise fashion.
Effective pain treatment consists of a fa-
Table 1—Pharmacological treatment options for painful neuropathy
Approach Compound/measure Dose per day Remarks NNT
Optimal diabetes control Diet, oral antidiabetic
drugs, insulin
Individual adaptation Aim: A1C 6.5–7%
Pathogenetically oriented treatment -Lipoic acid
(thioctic acid)*
600 mg i.v. infusion
600–1,800 mg orally
Duration: 3 weeks
Favorable safety proﬁle
6.3†
2.8–4.2†
First-line symptomatic treatment
TCAs Amitriptyline (10-)25–150 mg NNMH: 15 2.1
Desipramine (10-)25–150 mg NNMH: 24 2.2/3.2
Imipramine (10-)25–150 mg CRR 1.3/2.4/3.0
Clomipramine (10-)25–150 mg NNMH: 8.7 2.1
Nortriptyline (10-)25–150 mg Plus ﬂuphenazine 1.2
Selective serotonin norepinephrine
reuptake inhibitors Duloxetine‡ (30-)60–120 mg NNMH (60 mg): 18 5.3 (60 mg)
NNMH (120 mg): 9 4.9 (120 mg)
Venlafaxine 75–225 mg NNMH (75–225 mg): 21 6.9 (75–225 mg)
NNMH (150–225 mg): 17 4.6 (150–225 mg)
2- ligands Pregabalin‡ (50-)300–600 mg NNMH (300 mg): 23 6.0 (300 mg)
NNMH (600 mg): 11 4.0 (600 mg)
Gabapentin (300-)1,800–3,600 mg Evidence weaker than for
pregabalin
3.8/4.0
Second-line symptomatic treatments
Local treatment Capsaicin (0.025%)
cream
q.i.d. topically Maximum duration: 6–8
weeks
Weak opioids Tramadol 50–400 mg NNMH: 7.8 3.1/4.3
Strong opioids Oxycodone 10–100 mg Add-on treatment pioid-
speciﬁc problems
2.6
*Available only in some countries; †50% symptom relief after 3 and 5 weeks; ‡licensed in U.S. and European Union; CRR, concentration-response relationship;
NNMH, number needed for major harm.
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adverse events without implying a maxi-
mum effect (18–21).
The various pharmacological treat-
ment options are summarized in Table 1.
The advantages and disadvantages of the
various drugs and drug classes used for
treatment of DPN under consideration of
the various comorbidities and complica-
tionsassociatedwithdiabetesaresumma-
rized in Table 2. Before any decision
regarding the appropriate treatment, the
diagnosis of the underlying neuropathic
manifestation should be established (18).
In contrast to the agents that have been
derived from the pathogenetic mecha-
nisms of diabetic neuropathy, those used
for symptomatic therapy were designed
to modulate the pain, without favorably
inﬂuencing the underlying neuropathy
(19). A number of trials have been con-
ducted to evaluate the efﬁcacy and safety
of these drugs, but only a few included
large patient samples.
The relative beneﬁt of active treat-
ment over a control in clinical trials is
usually expressed as the relative risk, the
relative risk reduction, or the odds ratio.
However, to estimate the extent of a ther-
apeutic effect (i.e., pain relief) that can be
translatedintoclinicalpractice,itisuseful
to apply a simple measure that helps the
physician to select the appropriate treat-
ment for the individual patient. Such a
practical measure is the “number needed
to treat” (NNT), i.e., the number of pa-
tients who need to be treated with a par-
ticular therapy to observe a clinically
relevant effect or adverse event in one pa-
tient (22). The NNTs and numbers
needed to harm for the individual agents
used in the treatment of DPN are given in
Table 1.
Tricyclic antidepressants
Psychotropic agents, among which tricy-
clic antidepressants (TCAs) have been
evaluated most extensively, constitute an
important component in the treatment of
chronic pain syndromes for 30 years.
Putative mechanisms of pain relief by an-
tidepressants include the inhibition of
norepinephrine and/or serotonin re-
uptake at synapses of central descending
pain control systems, and the antagonism
ofN-methyl-D-aspartatereceptorthatme-
diateshyperalgesiaandallodynia.Imipra-
mine, amitriptyline, and clomipramine
induce a balanced reuptake inhibition of
both norepinephrine and serotonin,
whereas desipramine is a relatively selec-
tive norepinephrine inhibitor. The NNT
(95%CI)fora50%painreliefbyTCAis
2.4 (2.0–3.0) (20). The number needed
to harm is 2.8 for minor AEs and 19 for
major AEs (Table 1). Thus, among 100
diabetic patients with neuropathic pain
who are treated with antidepressants, 30
will experience pain relief by 50%, 30
willhavemildAEs,and5willdiscontinue
treatment due to severe AEs. The mean
NNT for drugs with balanced reuptake
inhibition is 2.2, whereas it is 3.6 for the
noradrenergic agents (20).
The most frequent AEs of TCAs in-
clude tiredness and dry mouth. The start-
ing dose should be 25 mg (10 mg in frail
patients) and taken as a single nighttime
dose 1 h before sleep. It should be in-
creasedby25mgatweeklyintervalsuntil
pain relief is achieved or AEs occur. The
maximum dose is usually 150 mg/day.
Amitriptyline is frequently the drug of
ﬁrst choice, but alternatively, desipra-
mine may be chosen for its less pro-
nounced sedative and anticholinergic
effects. The effect is comparable in pa-
tients with and without depression and is
independent of a concomitant improve-
ment in mood. The onset of efﬁcacy is
more rapid (within 2 weeks) than in the
treatmentofdepression.Themediandose
for amitriptyline is 75 mg/day, and there
is a clear dose-response relationship. In
two studies of imipramine, the dose was
adjusted to obtain the optimal plasma
concentration of 400–500 nmol/l to en-
sure maximum effect. The target concen-
tration could be attained in 57% of the
patients (20).
The notion that the character of the
neuropathic pain is predictive of re-
sponse, so that burning pain should be
treatedwithantidepressantsandshooting
pain with anticonvulsants, is obviously
unfounded, since both pain qualities re-
spond to TCAs. Most evidence of efﬁcacy
of antidepressants comes from studies
that have been conducted over only sev-
eral weeks. However, many patients con-
tinue to achieve pain relief for months to
years, although this is not true for every-
one. Tricyclic antidepressants should be
used with caution in patients with ortho-
static hypotension and are contraindi-
cated in patients with unstable angina,
recent (6 months) myocardial infarc-
tion, heart failure, history of ventricular
arrhythmias, signiﬁcant conduction sys-
tem disease, and long QT syndrome.
Thus, their use is limited by relatively high
rates of AEs and several contraindications.
Selective serotonin reuptake
inhibitors
Because of the relative high rates of AEs
and several contraindications of TCA, it
has been questioned whether patients
who are unable to tolerate these could al-
ternatively be treated with selective sero-
tonin reuptake inhibitors. These agents
speciﬁcally inhibit presynaptic reuptake
ofserotonin,butnotnorepinephrine,and
unlike the tricyclics, they lack the
postsynaptic receptor blocking effects
and quinidine-like membrane stabiliza-
tion.Threestudiesshowedthattreatment
with paroxetine and citalopram, but not
ﬂuoxetine, resulted in signiﬁcant pain re-
duction.Paroxetineappearedtoinﬂuence
both steady and lancinating pain qualities
(20). The therapeutic effect was observed
within 1 week and was dependent on the
plasma levels, being maximal at concen-
trations of 300–400 nmol/l. In addition
to the relatively low rates of AEs, the ad-
vantageofselectiveserotoninreuptakein-
hibitors compared with the tricyclic
compounds is the markedly lower risk of
Table 2—Treatment of painful neuropathy under consideration of comorbidities, side effects,
and drug metabolism
Duloxetine Pregabalin Tricyclics Opioids
-Lipoic
acid
Depression  n  nn
Obesity N  nn
Generalized anxiety disorder  NA NA NA
Sleep disturbances    NA
Coronary heart disease n N  nn
Autonomic neuropathy NA NA 
Fasting glucose ()* n ()* N n**
Hepatic failure  n§ § n
Renal failure  Adapt dose § § n
Drug interactions  n  nn
Effect:,favorable;,unfavorable;n,neutral;NA,notavailable;*slightincreasepossible;**slightdecrease
possible; §dependent on individual agent.
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cent case-control study suggested that se-
lective serotonin reuptake inhibitors
moderately increased the risk of upper
gastrointestinal bleeding to a degree ap-
proximately equivalent to low-dose ibu-
profen. The concurrent use of nonsteroidal
anti-inﬂammatory drugs, or aspirin, greatly
increases this risk. Because of these limited
efﬁcacy data, selective serotonin reuptake
inhibitors have not been licensed for the
treatment of neuropathic pain.
Serotonin norepinephrine reuptake
inhibitors
Because selective serotonin reuptake in-
hibitors have been found to be less ef-
fective than TCAs, recent interest has
focusedonantidepressantswithdualse-
lectiveinhibitionofserotoninandnorepi-
nephrine (serotonin norepinephrine
reuptake inhibitors), such as duloxetine
andvenlafaxine.Theefﬁcacyandsafetyof
duloxetine was evaluated in three con-
trolled studies using a dose of 60 and 120
mg/day over 12 weeks (23). In all three
studies, the average 24-h pain intensity
was signiﬁcantly reduced with both
doses, compared with placebo treatment,
thedifferencebetweenactiveandplacebo
achieving statistical signiﬁcance after 1
week. The response rates deﬁned as
50% pain reduction were 48.2% (120
mg/day), 47.2% (60 mg/day), and 27.9%
(placebo), giving an NNT of 4.9 (95% CI
3.6–7.6) for 120 mg/day and 5.2 (3.8–
8.3) for 60 mg/day (23). The numbers
needed to harm based on discontinuation
due to AEs were 8.8 (6.3–14.7) for 120
mg/day duloxetine and 17.5 (10.2–58.8)
for 60 mg/day (23). Pain severity, rather
than variables related to diabetes or neu-
ropathy, predicts the effects of duloxetine
in diabetic peripheral neuropathic pain.
Patientswithhigherpainintensitytendto
respondbetterthanthosewithlowerpain
levels (24). The most frequent AEs of du-
loxetine (60/120 mg/day) include nausea
(16.7/27.4%),somnolence(20.2/28.3%),
dizziness (9.6/23%), constipation (14.9/
10.6%), dry mouth (7.1/15%), and re-
duced appetite (2.6/12.4%). These AEs
are usually mild to moderate and tran-
sient. To minimize these effects, the start-
ing dose should be 30 mg/day for 4–5
days. In contrast to TCAs and some anti-
convulsants, duloxetine does not cause
weightgain,butasmallincreaseinfasting
blood glucose may occur (25).
In a 6-week trial comprising 244 pa-
tients, the analgesic response rates were
56, 39, and 34% in patients given 150–
225 mg venlafaxine, 75 mg venlafaxine,
and placebo, respectively. Because pa-
tients with depression were excluded, the
effect of venlafaxine (150–225 mg) was
attributed to an analgesic, rather than to
an antidepressant effect. The most com-
mon AEs were tiredness and nausea (26).
Duloxetine, but not venlafaxine, has been
licensed for the treatment of DPN.
Calcium-channel modulators
(2- ligands)
Gabapentinisananticonvulsantstructur-
allyrelatedto	-aminobutyricacid,aneu-
rotransmitter that plays a role in pain
transmission and modulation. The exact
mechanisms of action of this drug in neu-
ropathic pain are not fully elucidated.
Amongothers,theyinvolveaninteraction
withthesystem L-aminoacidtransporters
and high afﬁnity binding to the 2- sub-
unit of voltage-activated calcium chan-
nels. In an 8-week multicenter dose
escalation trial including 165 patients
with DPN, 60% of the patients on gabap-
entin (3,600 mg/day achieved in 67%)
had at least moderate pain relief com-
pared with 33% on placebo. Dizziness
and somnolence were the most frequent
AEs observed in 23% of the patients
(27).
Pregabalin is a more speciﬁc 2- li-
gandwithasixfoldhigherbindingafﬁnity
than gabapentin. The efﬁcacy and safety
of pregabalin was reported in a pooled
analysis of seven studies over 5–13 weeks
in1,510patientswithDPN.Theresponse
rates deﬁned as 50% pain reduction
were 47% (600 mg/day), 39% (300 mg/
day), 27% (150 mg/day), and 22% (pla-
cebo),givinganNNTof4.0,5.9,and20.0
(28).ThemostfrequentAEsfor150–600
mg/day were as follows: dizziness
(22.0%), somnolence (12.1%), periph-
eral edema (10.0%), headache (7.2%),
and weight gain (5.4%) (29). The evi-
dence supporting a favorable effect in
DPNisfarmoresolid,anddosetitrationis
considerably easier for pregabalin than
gabapentin, which is frequently under-
dosed in clinical practice.
Sodium channel blockers
Althoughcarbamazepinehasbeenwidely
used for treating neuropathic pain, it can-
not be recommended in DPN due to the
limited available data. Its successor drug,
oxcarbazepine (30), as well as other so-
dium channel blockers, such as topira-
mate (31) and lamotrigine (32), showed
only marginal or no efﬁcacy and, hence,
have not been licensed for the treatment
of DPN.
Potential systemic AEs associated
withintravenouslidocainehaveledtothe
development of a newer and potentially
saferagent,thetopicallidocainepatch5%
(Lidoderm), a targeted peripheral analge-
sic. In patients with postherpetic neuralgia,
the lidocaine patch 5% has demonstrated
relief of pain and tactile allodynia with a
minimal risk of systemic AEs or drug inter-
actions (33). Studies in patients with DPN
are under way.
Topical capsaicin
Capsaicin (trans-8-methyl-N-vanillyl-6-
nonenamide) is an alkaloid and the most
pungent ingredient in the red pepper. It
depletes tissues of substance P and re-
duces neurogenic plasma extravasation,
the ﬂare response, and chemically in-
duced pain. Substance P is present in af-
ferent neurons innervating skin, mainly
in polymodal nociceptors, and is consid-
ered the primary neurotransmitter of
painful stimuli from the periphery to the
central nervous system. Several studies
have demonstrated signiﬁcant pain re-
duction and improvement in quality of
life in patients with DPN after 8 weeks
of treatment with capsaicin cream
(0.075%). Six double-blind placebo-
controlled trials (656 patients) were
pooled for analysis of neuropathic condi-
tions. The relative beneﬁt of topical cap-
saicin (0.075%) compared with placebo
was 1.4 (95% CI 1.2–1.7) and the NNT
was 5.7 (4.0–10.0) (28). Treatment
should be restricted to a maximum of 8
weeks, since during this period, no ad-
verse effects on sensory function (due to
the mechanism of action) were noted in
diabetic patients. However, a skin blister
study in healthy subjects showed that
there is a 74% decrease in the number of
nerve ﬁbers as early as 3 days after topical
capsaicin application, suggesting that de-
generation of epidermal nerve ﬁbers may
contributetotheanalgesiainducedbythe
drug (34). This ﬁnding questioning the
safety of capsaicin in the context of an
insensitive diabetic foot limits its use.
Opioids
Tramadol acts directly via opioid recep-
tors and indirectly via monoaminergic re-
ceptor systems. Because the development
oftoleranceanddependenceduringlong-
term tramadol treatment is uncommon
and its abuse liability appears to be low, it
is an alternative to strong opioids in neu-
ropathic pain. In DPN, tramadol (up to
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day orally) has been studied in a 6-week
multicenter trial including 131 patients
(35).Painreliefwas44%ontramadolver-
sus 12% on placebo. The most frequent
AEs were nausea and constipation. The
numberneededtoharmof7.8fordropouts
due to AEs was relatively low, indicating
signiﬁcant toxicity. One conceivable mech-
anism for the favorable effect of tramadol
could be a hyperpolarization of postsynap-
tic neurons via postsynaptic opioid recep-
tors. Alternatively, the reduction in central
hyperexcitability by tramadol could be due
to a monoaminergic or a combined opioid
and monoaminergic effect.
Mostseverepainrequiresadministra-
tionofstrongopioids,suchasoxycodone.
Although there is little data available on
combination treatment, combinations of
differentsubstanceclassesshouldbeused
in patients with pain resistant to mono-
therapy. Two trials over 4 and 6 weeks
have demonstrated signiﬁcant pain relief
and improvement in quality of life after
treatment with controlled-release oxyc-
odone,apure
agonist,inadoserangeof
10–100mg(mean40mg/day)inpatients
with DPN whose pain was not adequately
controlledonstandardtreatmentwithan-
tidepressants and anticonvulsants that
were not discontinued throughout the
trial (36,37). As expected, AEs were fre-
quentandtypicalofopioid-relatedAEs.A
recent study examined the maximum tol-
erable dose of a combination treatment of
gabapentinandmorphinecomparedwith
monotherapy of each drug. The maxi-
mum tolerable dose was signiﬁcantly
lowerandefﬁcacywasbetterduringcom-
bination therapy than with monotherapy,
suggesting an additive interaction be-
tween the two drugs (38). The results of
these studies suggest that opioids should
be included among the therapeutic op-
tionsforDPN,providedthatcarefulselec-
tion of patients unresponsive to standard
treatments,regularmonitoring,appropri-
atedosetitration,andmanagementofAEs
are ensured. Combination therapy using
antidepressants and anticonvulsants may
also be useful, particularly if mono-
therapy is not tolerated due to AEs.
Lacosamide
Lacosamide is a novel anticonvulsant that
selectively enhances the slow inactivation
of voltage-dependent sodium channels,
but in contrast to the aforementioned so-
dium channel blockers, does not inﬂu-
encethefastsodiumchannelinactivation.
Its second putative mechanism is an in-
teraction with a neuronal cytosolic pro-
tein, the collapsin response mediator
protein 2 (crmp-2), which plays an im-
portant role in nerve sprouting and excito-
toxicity. Lacosamide has been evaluated in
several studies in DPN, three of whichhave
been published (39–41). In a phase II
trial, lacosamide (n  60) (100–400 mg/
day or maximal tolerated dose) was com-
pared with placebo treatment (n  59).
The pain relief on the Likert scale was
1.21pointswithlacosamideand0.87
points with placebo (P  0.039). Most
frequent AEs versus placebo were head-
ache (18 vs. 22%), vertigo (15 vs. 8%),
and nausea (12 vs. 7%). However, the
drug was not approved by the Food and
Drug Administration and European Med-
icines Agency for DPN in 2008, but fur-
ther clinical trials may follow in the
future.
CONCLUSIONS — Advanced knowl-
edge in neurobiology of neuropathic pain
and an increasing perception of the com-
mercial value of analgesic agents have led
to a burst of research into novel pharma-
ceutical approaches. According to a recent
review (42), at least 50 new molecular en-
titieshavereachedtheclinicalstageofde-
velopment, including glutamate
antagonists, cytokine inhibitors, va-
nilloid-receptor agonists, catecholamine
modulators, ion-channel blockers, anti-
convulsants, opioids, cannabinoids, COX
inhibitors, acetylcholine modulators,
adenosine receptor agonists, and several
miscellaneous drugs. Eight drugs are
presentlyinphaseIIItrials.Strategiesthat
may show promise over existing treat-
ments include topical therapies, analgesic
combinations, and, in the future, gene-
related therapies. Although several novel
analgesic drugs have recently been intro-
duced into clinical practice, the pharma-
cologic treatment of chronic DPN
remains a challenge for the physician. In-
dividual tolerability remains a major as-
pect in any treatment decision. Whether
the efﬁcacy and safety of the newer and
older compounds differ has not been sys-
tematically addressed in comparative tri-
als, but clinical experience indicates that
the rates of AEs of the newer compounds
maybelowerthanthoseoftheolderones,
such as tricyclic antidepressants. Almost
no information is available from con-
trolled trials on long-term analgesic efﬁ-
cacy. Only a few studies have used drug
combinations, indicating that the latter
may result in enhanced efﬁcacy.
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